Table 4.
AHRQ checklist scoring
| 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | Scores | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Zhu [28] | Y | Y | Y | UC | N | Y | Y | Y | Y | Y | UC | 8 |
| Liang [29] | Y | Y | Y | UC | N | Y | N | Y | N | N | UC | 5 |
| Luo et al. [30] | Y | Y | Y | Y | N | Y | N | Y | N | N | UC | 6 |
| Tang et al. [31] | Y | Y | Y | UC | N | Y | N | Y | N | N | UC | 5 |
| Han et al. [32] | Y | Y | Y | Y | Y | Y | N | Y | N | Y | UC | 8 |
| Chang [33] | Y | Y | Y | N | Y | N | Y | Y | N | Y | UC | 7 |
| Yan et al. [34] | Y | Y | Y | UC | Y | N | Y | Y | N | Y | UC | 7 |
| Ji et al. [35] | Y | Y | Y | UC | N | Y | Y | N | Y | N | UC | 6 |
| Zhu et al. [36] | Y | Y | N | UC | N | Y | N | Y | N | N | UC | 4 |
| Cao et al. [37] | Y | Y | Y | UC | N | Y | N | Y | N | N | UC | 5 |
| Xiong et al. [38] | Y | Y | Y | Y | N | Y | N | Y | Y | N | Y | 8 |
| Wang et al. [39] | Y | Y | Y | UC | Y | Y | N | Y | N | Y | UC | 7 |
| Wu et al. [40] | Y | Y | Y | UC | Y | Y | N | Y | N | Y | UC | 7 |
| Wu et al. [41] | Y | Y | Y | UC | N | Y | Y | Y | N | Y | UC | 7 |
| Wu et al. [42] | Y | Y | Y | Y | N | Y | N | Y | N | Y | UC | 7 |
| Chen et al. [43] | Y | Y | Y | Y | N | Y | Y | Y | N | Y | UC | 8 |
| Ding et al. [44] | Y | Y | Y | Y | Y | Y | N | Y | N | Y | UC | 8 |
| Gao et al. [45] | Y | Y | Y | UC | Y | Y | N | Y | N | N | UC | 6 |
| Gao et al. [46] | Y | Y | Y | UC | N | Y | N | Y | N | N | UC | 5 |
| Li et al. [47] | Y | Y | Y | UC | N | Y | N | Y | N | Y | UC | 6 |
| He et al. [48] | Y | N | Y | UC | N | Y | N | N | N | Y | UC | 4 |
| Wang [49] | Y | Y | Y | Y | Y | Y | N | Y | N | N | UC | 7 |
| Wang et al. [50] | Y | Y | Y | UC | N | Y | N | Y | N | N | UC | 5 |
| Zhang et al. [51] | Y | Y | Y | Y | N | Y | N | Y | N | Y | UC | 7 |
| He et al. [52] | Y | Y | N | UC | Y | Y | N | N | N | N | UC | 4 |
| Wei [53] | Y | Y | Y | Y | Y | Y | Y | Y | N | Y | Y | 10 |
| Che et al. [54] | Y | Y | Y | Y | N | Y | N | Y | N | N | UC | 6 |
| Yu et al. [55] | Y | Y | Y | Y | N | Y | N | Y | N | N | UC | 6 |
| Chen [56] | Y | Y | Y | Y | Y | Y | N | Y | N | Y | UC | 8 |
| Chen et al. [57] | Y | Y | Y | Y | N | Y | N | Y | N | Y | UC | 7 |
| Cui [58] | Y | Y | Y | UC | N | Y | N | Y | N | Y | UC | 6 |
| Gu [59] | Y | Y | Y | Y | Y | Y | N | Y | N | N | UC | 7 |
| Jiang [60] | Y | Y | Y | Y | Y | Y | Y | Y | N | Y | UC | 9 |
| Wang et al. [61] | Y | Y | Y | Y | Y | N | Y | N | N | N | UC | 7 |
| Farooq et al. [62] | Y | Y | Y | UC | N | Y | N | N | N | Y | UC | 6 |
| Zhao et al. [63] | Y | Y | Y | Y | Y | Y | Y | Y | N | Y | UC | 9 |
| Lin et al. [64] | Y | Y | Y | Y | N | Y | N | Y | N | N | Y | 7 |
| Sun et al. [65] | Y | Y | Y | UC | Y | Y | N | Y | N | N | UC | 6 |
Y yes, UC unclear, N no, AHRQ agency for health research and quality. AHRQ checklist items 1—Define the source of information, 2—List inclusion and exclusion criteria for exposed and unexposed subjects or refer to previous publications. 3—Indicate time period used for identifying patients. 4—Indicate whether or not subjects were consecutive if not population-based. 5—Indicate if evaluators of subjective components of study were masked to other aspects of the status of the participants. 6—Describe any assessments undertaken for quality assurance purposes. 7—Explain any patient exclusions from analysis. 8—Describe how confounding was assessed and/or controlled. 9—If applicable, explain how missing data were handled in the analysis. 10—Summarize patient response rates and completeness of data collection. 11—Clarify what follow-up, if any, was expected and the percentage of patients for which incomplete data or follow-up was obtained